Patents by Inventor Brian D. Frenzel

Brian D. Frenzel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240091228
    Abstract: The present invention relates to compositions, formulations, and methods for treating drug-induced ILF/IPF disorders by administration of a UPase inhibitor, with or without supplemental uridine, a uridine prodrug or a uridine mimetic to a subject in need thereof. Candidate drugs for the treatment include bleomycin and analogs, methotrexate and analogs, and amiodarone and analogs.
    Type: Application
    Filed: September 1, 2023
    Publication date: March 21, 2024
    Inventors: William A. Garland, Philip Liaw, Brian D. Frenzel
  • Publication number: 20230255971
    Abstract: Methods of treating a subject for a liver condition, e.g., NAFLD, NASH, and/or DILI, are provided. Aspects of the methods include administering to the subject an effective amount of a UPase inhibitor, optionally in combination with a uridine active agent (e.g., uridine (UR), a UR pro-drug or a UR mimetic), such as supplemental uridine, to treat the subject for the liver condition. Also provided are compositions for use in practicing the subject methods.
    Type: Application
    Filed: August 12, 2022
    Publication date: August 17, 2023
    Inventors: William A. Garland, Heshan Peiris, Philip Liaw, Brian D. Frenzel
  • Patent number: 11446303
    Abstract: Methods of treating a subject for a liver condition, e.g., NAFLD, NASH, and/or DILI, are provided. Aspects of the methods include administering to the subject an effective amount of a UPase inhibitor, optionally in combination with a uridine active agent (e.g., uridine (UR), a UR pro-drug or a UR mimetic), such as supplemental uridine, to treat the subject for the liver condition. Also provided are compositions for use in practicing the subject methods.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: September 20, 2022
    Assignee: Tosk, Inc.
    Inventors: William A. Garland, Heshan Peiris, Philip Liaw, Brian D. Frenzel
  • Publication number: 20220227740
    Abstract: RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.
    Type: Application
    Filed: April 13, 2020
    Publication date: July 21, 2022
    Inventors: Solomon B. Ungashe, William A. Garland, Stephen D. Yanofsky, Brian D. Frenzel, Philip Liaw, Annie L. Lennek
  • Publication number: 20220008422
    Abstract: The present invention relates to compositions, formulations, and methods for treating pulmonary disorders having fibrosis as part of the underlying pathology, such as IPF and ARDS, by administration of a UPase inhibitor, with or without supplemental UR, a UR prodrug, or a UR mimetic to a subject in need thereof.
    Type: Application
    Filed: July 7, 2021
    Publication date: January 13, 2022
    Inventors: William A. Garland, Philip Liaw, Brian D. Frenzel
  • Publication number: 20210261532
    Abstract: RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.
    Type: Application
    Filed: August 6, 2019
    Publication date: August 26, 2021
    Inventors: Annie L. Lennek, Stephen D. Yanofsky, Brian D. Frenzel, Solomon B. Ungashe, William A. Garland, Philip Liaw
  • Publication number: 20210236530
    Abstract: Methods for treating a subject for mucositis are provided. Aspects of the methods include administering an effective amount of a cancer therapy toxicity-reducing adjuvant in combination with uridine or a prodrug thereof to the subject. In certain embodiments, the cancer therapy toxicity-reducing adjuvant is a 2,2?-anhydropyrimidine, or a derivative thereof. Also provided are compositions for use in practicing the subject methods. The subject methods and compositions find use in a variety of different cancer therapy applications.
    Type: Application
    Filed: February 12, 2021
    Publication date: August 5, 2021
    Inventors: William A. Garland, Brian D. Frenzel, Philip Liaw
  • Publication number: 20210228584
    Abstract: Methods for improving the therapeutic effectiveness of uridine administered to prevent and/or reduce various maladies including adverse event from drugs are provided. Aspects of the methods include administering an effective amount of a uridine maximizing adjuvant, e.g., a 2,2?-anhydropyrimidine, or a derivative thereof, to the subject. Also provided are compositions for use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications, including the treatment of a variety of different disease conditions.
    Type: Application
    Filed: February 12, 2021
    Publication date: July 29, 2021
    Inventors: William A. Garland, Brian D. Frenzel, Philip Liaw
  • Publication number: 20210228583
    Abstract: Methods for reducing radiation therapy induced toxicity, e.g., mucositis, in a subject are provided. Aspects of the methods include administering an effective amount of a radiation toxicity-reducing adjuvant to the subject. In certain embodiments, the radiation toxicity-reducing adjuvant is a 2,2?-anhydropyrimidine, or a derivative thereof. Also provided are compositions for use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications, including the treatment of a variety of different disease conditions.
    Type: Application
    Filed: February 12, 2021
    Publication date: July 29, 2021
    Inventors: William A. Garland, Brian D. Frenzel, Philip Liaw
  • Publication number: 20200397790
    Abstract: Methods of treating a subject for a liver condition, e.g., NAFLD, NASH, and/or DILI, are provided. Aspects of the methods include administering to the subject an effective amount of a UPase inhibitor, optionally in combination with a uridine active agent (e.g., uridine (UR), a UR pro-drug or a UR mimetic), such as supplemental uridine, to treat the subject for the liver condition. Also provided are compositions for use in practicing the subject methods.
    Type: Application
    Filed: June 17, 2020
    Publication date: December 24, 2020
    Inventors: William A. Garland, Heshan Peiris, Philip Liaw, Brian D. Frenzel
  • Patent number: 9468613
    Abstract: Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: October 18, 2016
    Assignee: Tosk, Inc.
    Inventors: William A. Garland, Brian D. Frenzel
  • Patent number: 9382287
    Abstract: Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2?-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: July 5, 2016
    Assignee: Tosk, Inc.
    Inventors: William A. Garland, Brian D. Frenzel, Travis Karg
  • Publication number: 20150258046
    Abstract: Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions.
    Type: Application
    Filed: May 20, 2015
    Publication date: September 17, 2015
    Inventors: William A. Garland, Brian D. Frenzel
  • Patent number: 9061038
    Abstract: Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: June 23, 2015
    Assignee: Tosk, Incorporated
    Inventors: William A. Garland, Brian D. Frenzel
  • Publication number: 20150072945
    Abstract: Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2?-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.
    Type: Application
    Filed: October 6, 2014
    Publication date: March 12, 2015
    Inventors: William A. Garland, Brian D. Frenzel, Travis Karg
  • Patent number: 8853227
    Abstract: Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2?-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.
    Type: Grant
    Filed: June 20, 2011
    Date of Patent: October 7, 2014
    Assignee: Tosk, Incorporated
    Inventors: William A. Garland, Brian D. Frenzel, Travis Karg
  • Publication number: 20120329744
    Abstract: Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions.
    Type: Application
    Filed: June 25, 2012
    Publication date: December 27, 2012
    Inventors: William A. Garland, Brian D. Frenzel
  • Patent number: 8227517
    Abstract: Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: July 24, 2012
    Assignee: Tosk, Incorporated
    Inventors: William A. Garland, Brian D. Frenzel
  • Publication number: 20110319419
    Abstract: Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2?-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.
    Type: Application
    Filed: June 20, 2011
    Publication date: December 29, 2011
    Inventors: William A. Garland, Brian D. Frenzel, Travis Karg
  • Patent number: RE48253
    Abstract: Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2?-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: October 13, 2020
    Assignee: Tosk, Inc.
    Inventors: William A. Garland, Brian D. Frenzel, Travis Karg